Author:
Alcindor Thierry,Witzig Thomas E.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference24 articles.
1. Dinse GE, Umbach DM, Sasco AJ, Hoel DG, Davis DL: Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators. Annu Rev Public Health 1999, 20:173–209.
2. Grillo-Lopez AJ, White CA, Varns C, et al.: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma [review]. Semin Oncol 1999, 26:66–73.
3. Maloney DG, Liles TM, Czerwinski DK, et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457–2466.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268–276.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献